Northland Securities Remains a Buy on MiMedx Group (MDXG)

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on MiMedx Group, with a price target of $12.00.

Claim 70% Off TipRanks This Holiday Season

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Byrnes covers the Healthcare sector, focusing on stocks such as MiMedx Group, Indivior, and Alvotech. According to TipRanks, Byrnes has an average return of -4.3% and a 37.17% success rate on recommended stocks.

In a report released on December 17, Mizuho Securities also maintained a Buy rating on the stock with a $10.00 price target.

Based on MiMedx Group’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $113.73 million and a net profit of $16.75 million. In comparison, last year the company earned a revenue of $84.06 million and had a net profit of $8.1 million

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MDXG in relation to earlier this year. Last month, Kimberly Maersk-Moller, the CCO of MDXG sold 58,300.00 shares for a total of $432,003.00.